technology and efficacy is too good, that a number of big pharma will rush to buy them out.
mid teens coming
wouldn't be surprised to see some major announcement in next 10 days, while interest is strong in this biotech
MIEP's pipeline of drugs for blood cancers is greatly undervalued here. Once they start releasing results of phase 2 trials this company will fly up as Johnson and Johnson, Celgene,Novartis and others are looking to acquire companies in this area.
With a full pipeline of drugs that are showing great results in blood cancers, this stock is highly likely to get bought out by Celgene, Novartis or J&J. When results of phase 2 for one of their compounds comes out any day this will fly to teens as institutional investors move in big into this recently IPO'd company.
Listen to investor conference in December to researchers and you realize they are amazed at the results they are seeing with their drug pipeline in the field of cancer.